RE: Announcement5 Sep 2020 15:22
People may have already guessed, but I’m particularly excited about 201. It has many different possible applications too, being in the family of tyrosine kinase (Src) inhibitors (more on this later...sorry, I’m in a particularly boring mood today, being stuck in the house) which have long been known to be successful in inhibiting the growth of tumours. This is why we can look into the possibilities of it being successful for endometriosis and breast cancer, inflammation responses and other things, as the pathways can be similar. 401 (sorry Valju!) I could take or leave.
I’m expecting much better results than DDDD (before anyone makes a note of me mentioning them again, sorry but it is relevant, although I do think they will be incredibly successful in other areas of their research, especially ibs) because their treatment for prostate cancer isn’t targeted enough. It produces a more general immune response, which is great and is why it needs to be used alongside another immunotherapy such as Keytruda (which only has about 40 ish percent success rate itself...) but 201 has the potential to achieve much better results in this particular scenario. This is because it’s the first use of a drug that actively targets the interaction of androgen receptors with the src protein. Src proteins drive tumour proliferation, there are other successful drugs That are on the market that effectively prevent tumour development in this way (Dasatinib and masitinib, for example). Both of these drugs are also being evaluated for potential other uses, as the Src protein is responsible for lots of things, which is why I’m excited about other possible uses for Val 201.
Dasatinib was actually trialled as a potential prostate cancer drug and eventually wasn’t successful enough. It completed three phases and the results from it’s phase two were seemingly worse than ours point to already. Their disease lack of progression was 43% after 12 weeks and 19% after 24 weeks. They progressed to a phase three from this. It is however a drug of choice and extremely successful at treating leukaemia and had an incredibly high success rate (huge market and does extremely well). Our drug would appear to be much better for prostate cancer because it targets the androgen interaction with the Src protein and inhibits the entire process, along with inhibiting the Src protein...whereas Dasatinib only targeted the Src protein to inhibit it.
All my own opinion obviously, but based on the increasing amount of research conducted to date
Sign In
Follow the stocks
